title: Generation of antigen-specific cytotoxic T lymphocytes using a leukemic plasmacytoid dendritic cell line as antigen presenting cells.
abstract: Establishment of a leukemia plasmacytoid dendritic cell line (PMDC05) and intra-lineage transformation from pDCs to mDCs in PMDC05 has been reported. In this paper, we show the applicability of PMDC05 for cellular immunotherapy. By stimulation with LPS, PMDC05 showed enhancement in expression of antigen presentation-associated surface molecules and production of cytokines (IL-12p70 and TNF-α). The antigen presenting ability was markedly increased in PMDC05 stimulated with LPS. By co-culturing of CD8(+) T cells with LPS-stimulated and WT1/CMVpp65 peptide-pulsed PMDC05, WT1/CMVpp65 tetramer(+) cytotoxic T lymphocytes were efficiently generated. These findings reveal the applicability of PMDC05 in cellular immunotherapy for tumor and severe viral infections.
authors.affiliation: Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, Chuou-ku, Niigata, Japan.
authors.forename: Akie
authors.initials: A
authors.lastname: Yamahira
authors.forename: Miwako
authors.initials: M
authors.lastname: Narita
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nakamura
authors.forename: Norihiro
authors.initials: N
authors.lastname: Watanabe
authors.forename: Masami
authors.initials: M
authors.lastname: Kaji
authors.forename: Tomoyo
authors.initials: T
authors.lastname: Taniguchi
authors.forename: Shigeo
authors.initials: S
authors.lastname: Hashimoto
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Furukawa
authors.forename: Ken
authors.initials: K
authors.lastname: Toba
authors.forename: Yoshifusa
authors.initials: Y
authors.lastname: Aizawa
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Kuzushima
authors.forename: Masuhiro
authors.initials: M
authors.lastname: Takahashi
mesh_terms: D017951:Antigen Presentation / Q000187:drug effects / Q000276:immunology; D000938:Antigen-Presenting Cells / Q000276:immunology* / Q000378:metabolism; D000941:Antigens / Q000276:immunology* / Q000378:metabolism; D000956:Antigens, Viral / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D018920:Coculture Techniques; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D016219:Immunotherapy, Adoptive / Q000379:methods; D018664:Interleukin-12 / Q000276:immunology / Q000378:metabolism; D007938:Leukemia / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008070:Lipopolysaccharides / Q000494:pharmacology; D010446:Peptide Fragments / Q000276:immunology; D010750:Phosphoproteins / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000378:metabolism; D014763:Viral Matrix Proteins / Q000276:immunology; D025721:WT1 Proteins / Q000276:immunology
chemical_list: D000941:Antigens; D000956:Antigens, Viral; D008070:Lipopolysaccharides; D010446:Peptide Fragments; D010750:Phosphoproteins; D014409:Tumor Necrosis Factor-alpha; D014763:Viral Matrix Proteins; C543100:WT1 (126-134), human; D025721:WT1 Proteins; C065418:cytomegalovirus matrix protein 65kDa; D018664:Interleukin-12